Bicara Therapeutics (BCAX) Common Equity (2023 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Common Equity of $514.0 million for Q1 2026, up 11.98% year-over-year from $459.0 million in Q1 2025, and up 28.02% quarter-over-quarter from $401.5 million in Q4 2025.
Bicara Therapeutics (BCAX) Common Equity (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Common Equity history runs 4 years deep, the most recent figure standing at $514.0 million for Q1 2026.
- In Q1 2026, Common Equity rose 11.98% year-over-year to $514.0 million; the TTM figure through Mar 2026 stood at $514.0 million (up 11.98% YoY), while the FY2025 annual figure was $401.5 million, down 18.38% from the prior year.
- Common Equity for Q1 2026 stood at $514.0 million, up from $401.5 million in the prior quarter.
- The five-year high for Common Equity was $514.0 million in Q1 2026, with the low at -$174.8 million in Q2 2024.
- The 4-year median for Common Equity is $402.8 million (2025), against an average of $235.7 million.
- The sharpest annual moves came in 2024 and 2025: Common Equity surged 471.64% in 2024, then declined 20.95% in 2025.
- Bicara Therapeutics' Common Equity stood at -$148.8 million in 2023, then surged by 430.63% to $491.9 million in 2024, then declined by 18.38% to $401.5 million in 2025, then rose by 28.02% to $514.0 million in 2026.
- Business Quant data shows BCAX's Common Equity at $514.0 million in Q1 2026, $401.5 million in Q4 2025, and $402.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - | 468.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 468.77 Mn |
| Mar 31, 2026 | 513.96 Mn |
| Dec 31, 2025 | 401.45 Mn |
| Sep 30, 2025 | 402.78 Mn |
| Jun 30, 2025 | 435.20 Mn |
| Mar 31, 2025 | 458.96 Mn |
| Dec 31, 2024 | 491.88 Mn |
| Sep 30, 2024 | 509.56 Mn |
| Jun 30, 2024 | -174.78 Mn |
| Mar 31, 2024 | -160.08 Mn |
| Dec 31, 2023 | -148.77 Mn |
| Sep 30, 2023 | -137.11 Mn |